Seroepidemiology And Co- Infections of Hepatitis D Virus Infection In The North- East of Iran

Document Type : Research Paper


1 Assistant Professor of Internal Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

2 Professor of Internal Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

3 Associate Professor of Internal Medicine, Mashhad University of Medical Sciences, Mashhad, Iran


HBV infection is the most common cause of chronic hepatitis in Iran. HDV prevalence in chronic carriers of HBV has not been studied in the north-east of Iran. This study evaluated the prevalence, risk factors and co-infections of HDV with HCV.
Materials and Methods
This cross-sectional study was carried out From Sep_ Oct 2004 to Sep_ Oct 2005. The patients divided into two groups, inactive chronic carrier and chronic liver disease (chronic hepatitis and/or liver cirrhosis). Our study included 350 chronic HBV carriers in whom we assessed HDV Ab by ELISA method, then HDV Ab positive patients were assessed for risk factors and Co-infections with HCV. Later risk factors and co-infections were compared in HDV positive and HDV negative patients.
Analysis of serum markers indicated that 10% (35/350) of patients had evidence of HDV infection; Anti-HDV was found in 4.5% (7/153) of patients with inactive carriers, and in 14.2% (28/197) of patients with chronic liver disease (chronic hepatitis and/or cirrhosis). Main risk factors of HDV positive and HDV negative infections included positive family history, blood transfusion, which were almost equal in two groups (p> 0.5). One out of thirty five (2.8%) of HDV positive patients showed triple infection of HBV/HDV/HCV. Also, 2.8% (1/35) of HDV negative patients showed dual infection of HBV/HCV
The present study shows that HDV infection is prevalent in the north-east of Iran, particularly in chronic hepatitis and cirrhosis, and it should be studied in them. Routine assessment of HCV in these patients is not recommended, unless risk factors exist.


1- Ponzetto A, Forzani B, Parravicini, P.P,Hele C, Zanetti A, Rizzetto M. Epidemiology of hepatitis delta virus (HDV)
infection. Eur J Epidemiol 1985; 1:257-263.
2- Robert P, Satheesh N, Hepatitis B. In:Mark F, Lawrence SF, Lawrence JB. editors. Gastrointestinal and liver disease.
8th ed. Piladelphia: Saunders: 2006 .p.1647-1648.
3- Gaeta GB, Stroffolini T, Chiaramonte M, Ascione T, Stornaiuolo G, Lobello S, et al. Chronic hepatitis D: A
vanishing disease? An Italian Multicenter Study. Hepatology 2000; 324:824-827.
4- Liaw YF, Chiu KW, Chu CM, Sheen IS, Huang MJ. Heterosexual transmission of hepatitis delta virus in the general
population of an area endemic for hepatitis B virus infection: A prospective study. J infect Dis 1990; 162:1170-1172.
5- Lok AS, Wong A, Sporton S, Lai CL, Liu V, Chung HT .Hepatitis D virus superinfection remains a rare occurrence
in non-drug abusers in Hong Kong. J Hepatol 1992; 14:332-334.
6- Casey JL, Brown TL, Colan EJ, Wignall FS, Gerin JL. A genotype of hepatitis D virus RNA that occurs in northern
south American. Proc Natl Acad Sci USA 1993; 90:9016-9020.
7- Polish LB, Gallagher M, Fields HA, Hadler SC. Delta hepatitis: molecular biology and clinical and epidemiological
features. Clin Microbiol Rev 1993; 6:211–229.
8- Chamberlain RW, Adams N, Saeed AA, Simmonds P, Elliott RM. Complete nucleotide sequence of a type 4
hepatitis C virus variant, the predominant genotype in the Middle East. J Gen Virol 1997; 78:1341-1347.
9- Worman HJ. Molecular biological methods in diagnosis and treatment of liver diseases. Clin Chem 1997; 43:1476-
10- Merat S, Malekzadeh R, Rezvan H, Khatibian M. Hpatitis B in IRAN. Arch Irn Med 2000; 3:192-201.
11- Azmi M, Hjiani E, Masjedi R, Hashemi SJ, Ghanbari A. Serolpidemiology of hepatitis D virus infection in chronic
HBV carriers in south-west of Iran (Khozestan province) (Abstract). Can J Gastroenterol 2005; 19
12- Amini S, Mahmoodi MF, Andalibi S, Solati AA. Seroepidemiology of hepatitis B, delta and human
immunodeficiency virus infections in Hamadan province, Iran: a population based study. J Trop Med Hyg 1993;
13- Rodriguez-Rosado R. Impact of antiretroviral treatment on hepatitis B virus infection in human immunodeficiency
virus-infected patients. Antivr Ther 1999; 4: 20.